3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Genitourinary
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
20
Triple Negative Breast Neoplasms
14
Ovarian Neoplasms
7
Melanoma
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Endometrial Neoplasms
3
Carcinoma, Hepatocellular
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
pembrolizumab
6
Paclitaxel
3
Docetaxel
3
Cyclophosphamide
3
eribulin
2
Oncolytic Virotherapy
2
tislelizumab
1
tirbanibulin
1
spartalizumab
1
poly ICLC
1
pertuzumab
1
pemigatinib
1
pegfilgrastim
1
obinutuzumab
1
ixabepilone
1
fludarabine phosphate
1
fludarabine
1
etirinotecan pegol
1
efineptakin alfa
1
durvalumab
1
atezolizumab
1
aldesleukin
1
advexin
1
Yoga
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Surveys and Questionnaires
1
Ritonavir
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Ipilimumab
×
Breast
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts